Standout Papers

Tislelizumab vs Sorafe... 2013 2026 2017 2021 572
  1. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma (2023)
    Shukui Qin, Masatoshi Kudo et al. JAMA Oncology
  2. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. (2024)
    Riccardo Lencioni, Masatoshi Kudo et al. Journal of Clinical Oncology
  3. Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial (2013)
    Ann‐Lii Cheng, Yoon‐Koo Kang et al. Journal of Clinical Oncology
  4. Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma (2019)
    Peter R. Galle, Friedrich Foerster et al. Liver International
  5. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial (2015)
    Jin Li, Shukui Qin et al. The Lancet Oncology
  6. Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial (2014)
    Călin Cainap, Shukui Qin et al. Journal of Clinical Oncology
  7. Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial (2013)
    Jin Li, Shukui Qin et al. Journal of Clinical Oncology
  8. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma (2021)
    Ann‐Lii Cheng, Shukui Qin et al. Journal of Hepatology
  9. Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia (2013)
    Shukui Qin, Yuxian Bai et al. Journal of Clinical Oncology
  10. SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma (2014)
    Andrew X. Zhu, Olivier Rosmorduc et al. Journal of Clinical Oncology
  11. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial (2020)
    Shukui Qin, Zhenggang Ren et al. The Lancet Oncology
  12. Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial (2022)
    Shukui Qin, Zhendong Chen et al. Journal of Clinical Oncology

Immediate Impact

11 from Science/Nature 81 standout
Sub-graph 1 of 15

Citing Papers

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide
2024 Standout

Works of Shukui Qin being referenced

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
2021 Standout
Infection and Cancer: The Case of Hepatitis B
2015
and 2 more

Author Peers

Author Last Decade Papers Cites
Shukui Qin 5054 3682 5069 334 11.5k
Ho Yeong Lim 6235 5478 4233 365 14.2k
Arndt Vogel 4235 2896 4419 377 12.2k
Junji Furuse 6490 3634 3857 415 12.4k
Ghassan K. Abou‐Alfa 5065 2954 3869 338 11.0k
Masafumi Ikeda 5907 2730 5546 475 12.4k
Ian Chau 12763 6982 3130 463 18.2k
Christophe Louvet 14592 5964 3574 278 17.4k
Michael J. Overman 10938 3816 2233 443 15.9k
Naofumi Nagasue 1995 2185 3814 283 9.8k
Jennifer J. Knox 7467 8114 4068 374 17.0k

All Works

Loading papers...

Rankless by CCL
2026